Lord, J.M., et al, “Ricin: Structure, Mode of Action, and Some Current Applications”, The FASEB Journal, vol. 8 pp. 201and 206, 2/94. |
Richardson, P.T, et al, “Recombinant Proricin Binds Galactose But Does Not Depurinate 28 S Ribosomal RNA,” FEBS 07564, vol. 255, No. 1, p. 15, 9/89. |
Westby, M.W., et al, “Preparation and Characterization of Recombinant, Proricin Containing an Alternative Protease-Sensitive Linker Sequence,” Bioconjugate Chemistry, 1992, 3, p. 375. |
Darket, P.L., et al., “Human Immunodeficiencey Virus Protease,” Journal of Biological Chemistry, vol. 264, No. 4, p. 2307 1989. |
Jordan, S.P., et al, “Activity and Dimerization of Human Immunodeficiency Virus Protease as a Function of Solvent Composition and Enzyme Concentration,” Journal of Biological Chemistry, vol. 267, No. 28, p. 20028. 1992. |
Van Quen, M.G., “Rationale for the Use of Immunotixins in the Treatment of HIV-Infected Humans,” Journal of Drug Targeting, vol. 5, No. 2 p. 75, 1997. |
Wachinger, M., et al, “Bryodin, a Single-Chaim Ribosome-Inactivating Protein, Selectively Inhibits the Grown of HIV-1-Infected Cells and Reduces HIV-1 Production,” Research in Experimental Medicine, 193:1-2, 1993. |
Till, M.A., et al, “HIV-Infected Cells are Killed by rCF4-Ricin A Chain,” Science, vol. 24 p. 1166. |